Enantioselective Hydrogen Atom Relay via Non-Covalent Catalyst Assembly

Why It Matters

The method provides enantioselective control over fleeting radical intermediates, a historic bottleneck in asymmetric HAT chemistry, accelerating chiral drug development. Its modular, non‑covalent design cuts synthetic steps, making asymmetric radical processes more scalable for industry.

Key Takeaways

• Chiral HAT catalysts formed by self‑assembly of phosphoric acids and thiols
• Non‑covalent assembly enables enantioselective hydrogen atom relay for deracemization
• Platform applied to photochemical deracemization of 2‑aryl pyrrolidines, pharma scaffolds
• Strategy opens combinatorial space for asymmetric radical transformations without covalent catalyst synthesis

Pulse Analysis

Asymmetric catalysis has long relied on covalently bound chiral ligands to steer reactions toward a single enantiomer, yet hydrogen atom transfer (HAT) processes have resisted such control because radicals exist only fleetingly. Traditional chiral HAT catalysts require elaborate synthesis and often deliver modest enantioselectivity, limiting their adoption in the synthesis of complex, chiral molecules. The EPFL team’s breakthrough sidesteps these constraints by leveraging non‑covalent self‑assembly, pairing readily available chiral phosphoric acids with 2‑mercaptopyridines to create a dynamic, yet highly ordered, catalytic pocket.

In this assembled system, the phosphoric acid imparts chirality to an otherwise achiral thiol, allowing the resulting complex to orchestrate both hydrogen abstraction and delivery in a single, stereochemically defined step. Photochemical activation generates the radical species, while the chiral assembly enforces a preferential pathway, achieving deracemization of 2‑aryl pyrrolidines with high optical purity. This elegant relay of chiral information demonstrates that precise stereocontrol can be achieved without permanent covalent modification of the catalyst, opening a new combinatorial landscape for designing asymmetric radical reactions.

The implications for the pharmaceutical and fine‑chemical sectors are substantial. Many active pharmaceutical ingredients feature tertiary stereogenic centers that are challenging to construct enantioselectively. By providing a modular, low‑cost platform that can be tuned through simple acid‑thiol pairings, the technology promises faster access to chiral intermediates and reduces the synthetic burden associated with traditional chiral catalyst development. Moreover, the concept of non‑covalent catalyst assembly may inspire analogous strategies across photoredox, electrochemical, and enzymatic domains, accelerating the broader adoption of asymmetric radical methodologies in industrial settings.